Morgan Stanley Issues Pessimistic Forecast for UnitedHealth Group (NYSE:UNH) Stock Price

Key Points

• Morgan Stanley trimmed its price target on UnitedHealth from $411 to $409 but kept an overweight rating, with the target implying about a 15% upside from the stock's current level.
• Analyst sentiment is broadly positive—a majority of analysts rate UNH Buy/Strong Buy and the MarketBeat consensus target is $386.33, while major banks like JPMorgan and Mizuho have raised targets into the $425–$430 range.
• Near-term risks and catalysts include rising medical costs, a planned rebate of 2026 ACA profits, congressional scrutiny, and the upcoming Q4 earnings report on Jan. 27, any of which could pressure margins or increase volatility.

UnitedHealth Group (NYSE:UNH - Get Free Report) had its price objective cut by Morgan Stanley from $411.00 to $409.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the healthcare conglomerate's stock. Morgan Stanley's price target suggests a potential upside of 15.07% from the stock's current price.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. increased their price objective on shares of UnitedHealth Group from $310.00 to $425.00 and gave the company an "overweight" rating in a report on Thursday, October 9th. Weiss Ratings reissued a "hold (c-)" rating on shares of UnitedHealth Group in a report on Wednesday. Mizuho increased their price target on UnitedHealth Group from $300.00 to $430.00 and gave the company an "outperform" rating in a research note on Thursday, October 9th. Barclays upped their price objective on UnitedHealth Group from $386.00 to $391.00 and gave the stock an "overweight" rating in a report on Monday, January 5th. Finally, KeyCorp upped their price target on shares of UnitedHealth Group from $350.00 to $400.00 and gave the company an "overweight" rating in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $386.33.

UnitedHealth Group Stock Performance

NYSE:UNH traded up $0.97 during mid-day trading on Friday, hitting $355.44. 3,755,189 shares of the company traded hands, compared to its average volume of 6,790,447. UnitedHealth Group has a one year low of $234.60 and a one year high of $606.36. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 0.71. The firm has a market cap of $321.97 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 2.10 and a beta of 0.42. The stock's fifty day moving average price is $331.37 and its 200-day moving average price is $322.96.

UnitedHealth Group (NYSE:UNH - Get Free Report) last released its earnings results on Tuesday, October 28th. The healthcare conglomerate reported $2.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.87 by $0.05. The company had revenue of $113.16 billion during the quarter, compared to analyst estimates of $113.19 billion. UnitedHealth Group had a net margin of 4.04% and a return on equity of 19.23%. The firm's quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.15 EPS. Research analysts anticipate that UnitedHealth Group will post 29.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Capital World Investors grew its stake in UnitedHealth Group by 18.8% during the 3rd quarter. Capital World Investors now owns 21,766,922 shares of the healthcare conglomerate's stock valued at $7,516,107,000 after purchasing an additional 3,439,182 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of UnitedHealth Group by 3.3% in the second quarter. Geode Capital Management LLC now owns 21,312,182 shares of the healthcare conglomerate's stock worth $6,624,411,000 after acquiring an additional 675,075 shares during the period. Capital International Investors lifted its position in UnitedHealth Group by 11.1% during the third quarter. Capital International Investors now owns 17,499,949 shares of the healthcare conglomerate's stock valued at $6,042,710,000 after purchasing an additional 1,747,337 shares during the period. Capital Research Global Investors lifted its holdings in shares of UnitedHealth Group by 126.9% in the 3rd quarter. Capital Research Global Investors now owns 13,042,049 shares of the healthcare conglomerate's stock valued at $4,503,419,000 after buying an additional 7,293,009 shares during the period. Finally, Norges Bank purchased a new stake in UnitedHealth Group in the 2nd quarter worth approximately $3,837,207,000. 87.86% of the stock is owned by institutional investors and hedge funds.

UnitedHealth Group News Roundup

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Mizuho reiterated a Buy on UNH and kept a $430 price target, highlighting optimism around the Medicare Advantage 2027 advance notice as a potential tailwind. Mizuho Remains Positive on UnitedHealth
• Positive Sentiment: UNH recently outperformed the broader market in intraday moves, indicating short-term buying interest ahead of earnings. UnitedHealth Group Outperforms Broader Market
• Neutral Sentiment: Multiple previews urge caution until the company reports Q4 results on Jan. 27 — analysts say key metrics beyond revenue/EPS (medical cost trends, MCR) will drive the next leg of the stock move. Countdown to UNH Q4 Earnings
• Neutral Sentiment: Market commentary advises waiting for the Jan. 27 earnings release before adding exposure, reinforcing the idea that near-term volatility could continue. Don't Buy UNH Before Jan. 27
• Negative Sentiment: Analysts warn rising medical costs and a higher medical cost ratio (MCR) could pressure margins heading into Q4 results — a direct risk to near-term earnings. Cost Pressures a Red Flag
• Negative Sentiment: UnitedHealth said it will rebate 2026 ACA plan profits, a move that could reduce near-term earnings and signal growing regulatory/cost headwinds. UNH to Rebate 2026 ACA Profits
• Negative Sentiment: Executives from UnitedHealth faced tough questions from Congress on affordability — a political/regulatory risk that can weigh on investor sentiment and future policy uncertainty. UnitedHealth and CVS Grilled by Congress
• Negative Sentiment: High-profile commentators prefer competitors (e.g., Jim Cramer favoring CVS), which can amplify short-term negative sentiment versus UNH. Cramer: Buy CVS, Not UnitedHealth

About UnitedHealth Group

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company's benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.